1887

n Cardiovascular Journal of South Africa - CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand(R)) : drug trends in cardiology

USD

 

Abstract

Extracted from text ... 252 Further analysis of the CHARM study focusing on patients with chronic heart failure (CHF) and impaired LV function in the CHARM-Alternative trial (patients received candesartan instead of an ACE inhibitor) and CHARMAdded (patients receiving candesartan plus ACE inhibitor) has shown a significant reduction in deaths and CHF hospital admissions in patients receiving this angiotensin-receptor blocker. The overall CHARM programme, announced at the European Society Congress (ESC) last year, had included a third, CHARM-Preserved trial, which investigated CHF patients with uncompromised left ventricular ejection fraction (LVEF above 40%). The pre-specified analysis of the 4 576 CHARM patients with heart failure ..

Loading

Article metrics loading...

/content/cardio/15/5/EJC23941
2004-09-01
2016-12-04
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error